Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio

Ibrutinib is an orally administered Bruton's tyrosine kinase inhibitor approved for the treatment of B‐cell malignancies, including chronic lymphocytic leukemia. Ibrutinib is metabolized primarily via oxidation by cytochrome P450 (CYP) 3A4/5 to M37 (the primary active metabolite), M34, and M25....

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jonghwa, Fallon, John K., Smith, Philip C., Jackson, Klarissa D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926076/
https://www.ncbi.nlm.nih.gov/pubmed/36350327
http://dx.doi.org/10.1111/cts.13448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926076/
https://www.ncbi.nlm.nih.gov/pubmed/36350327
http://dx.doi.org/10.1111/cts.13448

Ejemplares similares